Inflammation Assay
Human Primary Cell Models for Immunology Research
Inflammation is a key pathological process involved in a wide range of acute and chronic diseases. Our assay provides a physiologically relevant human model to study immune activation directly in freshly collected human blood or isolated PBMCs (Peripheral Blood Mononuclear Cells), offering highly predictive insights into the human inflammatory response.
Key Features of our Inflammation assay:
- Inflammatory panels (IFN-γ, TNF-α, IL-1β, IL-6, IL-8, IL-10 and more).
- Cytokine and Chemokine panels (MCP-1, IL-8, IP-10 and more)
- High-throughput and reproducible: Optimized for rapid evaluation of immunomodulatory therapeutic candidates.
Results are delivered as quantified cytokine concentrations across a validated multiplex panel, with dose-response curves and Go/No-Go interpretation included as standard.
Contact us to learn more about our inflammation assay.
Downoad the poster of our in vitro inflammation assay
The assay can be customized to suit specific experimental requirements, allowing for the assessment of various cell types, treatments, and conditions.
Highly sensitive ELISA or Multiplex dosage of secreted cytokines by ELLA-multiplex
With multiplex capabilities, our assay enables simultaneous quantification of multiple cytokines, providing a comprehensive profile of the inflammatory response.
Example of Study design
Example of Assay readouts
Human whole blood induced by LPS for 24h:
Frequently Asked Questions – Inflammation assay
Our standard protocols use LPS (lipopolysaccharide) at 1 ng/mL to activate TLR4-mediated innate immune responses in whole blood, and PHA (phytohaemagglutinin) at 5 µg/mL to stimulate T cell-mediated responses in PBMCs. Other stimuli, including Poly(I:C), R848, or client-specific antigens, can be incorporated on request to match your disease or pathway of interest.
Yes. By including both pro-inflammatory (e.g. TNF-α, IL-1β, IL-6) and anti-inflammatory (e.g. IL-10) markers in the same panel, the assay can profile a compound’s overall immunomodulatory activity including whether it shifts the balance toward immune suppression or resolution, which is critical for compounds targeting autoimmune or chronic inflammatory conditions.
Cell viability is assessed in parallel with cytokine readouts at each compound concentration, using validated viability assays. This ensures that any observed reduction in cytokine secretion reflects genuine immunosuppressive activity rather than cytotoxicity. Concentrations causing >20% viability loss are flagged and excluded from the immunomodulation analysis.
Yes. The inflammation assay is frequently combined with our fibrosis assay (to characterise compounds that target both immune activation and downstream ECM deposition) or our nephrotoxicity screening panel (to generate a combined efficacy and renal safety profile). Multi-assay packages reduce overall cost and timeline compared to sequential studies, and biomarker endpoints are harmonised across assays for direct cross-platform comparison.
Related in vitro assays